Skip to main content
CRDF
NASDAQ Life Sciences

Onvansertib Phase 2 Trial Shows 72.2% ORR in mCRC, FDA Aligns on Phase 3 Design

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1.53
Mkt Cap
$101.187M
52W Low
$1.4
52W High
$4.555
52W Position info
9.3% above low
Off High info
66% below high
Rel. Volume info
6.9× avg
Market data snapshot near publication time

CRDF is trading near its 52-week low of $1.4 (9.3% above the low) on elevated volume (6.9× avg).

Summary

Cardiff Oncology announced strong positive Phase 2 results for its lead drug, Onvansertib, in first-line RAS-mutated metastatic colorectal cancer, achieving a 72.2% objective response rate versus 42.1% for standard-of-care. The drug was well-tolerated, and the company has aligned with the FDA on the design for a registrational Phase 3 trial. This significant clinical de-risking for Onvansertib follows the May 15th news of FDA agreement on the Phase 3 design. However, this positive data is overshadowed by the May 29th 8-K, which revealed the termination of the license agreement for Onvansertib by its licensor, creating a major hurdle for the drug's commercial future despite its clinical promise.

At the time of this announcement, CRDF was trading at $1.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.2M. The 52-week trading range was $1.40 to $4.56. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CRDF - Latest Insights

CRDF
Nov 16, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.8328
Real-time Price: $0.85051 info
Change: +$0.01771 (+2%) info
Market Cap: $69.44M info
CRDF
Nov 12, 2026, 4:21 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7276
Real-time Price: $0.85051 info
Change: +$0.12291 (+17%) info
Market Cap: $69.44M info
CRDF
Nov 12, 2026, 4:20 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.7276
Real-time Price: $0.85051 info
Change: +$0.12291 (+17%) info
Market Cap: $69.44M info
CRDF
Nov 12, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7695
Real-time Price: $0.85051 info
Change: +$0.08101 (+11%) info
Market Cap: $69.44M info
CRDF
Oct 27, 2026, 4:44 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8988
Real-time Price: $0.85051 info
Change: -$0.04829 (-5%) info
Market Cap: $69.44M info